Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
Key Highlights
- ➤TONMYA Phase 3 fibromyalgia analysis scheduled for presentation at IASP Congress
- ➤TONMYA FDA-approved August 15, 2025, and commercially launched November 17, 2025
- ➤TONMYA is the first new prescription fibromyalgia medicine approved in more than 15 years
- ➤TONMYA patents are expected to provide U.S. market exclusivity until 2034
Expert Statements
Errol Gould, Ph.D., Senior Vice President, Medical Affairs, Tonix Medicines
“Cyclobenzaprine HCl Sublingual Reduces Fibromyalgia Impact on Physical Symptoms & Functional Ability”
BERKELEY HEIGHTS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, held October 26-30, 2026, in Bangkok, Thailand. TONMYA was approved by the U.S. Food and Drug Administration on August 15, 2025, and commercially launched in the U.S. on November 17, 2025.
Title: Cyclobenzaprine HCl Sublingual Reduces Fibromyalgia Impact on Physical Symptoms & Functional Ability Poster #: 157 Poster Session: 2 Date: October 27, 2026 Time: 3:15-4:45 p.m. ICT Presenter: Errol Gould, Ph.D., Senior Vice President, Medical Affairs, Tonix Medicines
Get started
Create a free account to read the full story.